Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases

被引:45
作者
Zhang, PJ
Barcos, M
Stewart, CC
Block, AW
Sait, S
Brooks, JJ
机构
[1] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Div Anat Pathol, Philadelphia, PA 19104 USA
[2] Roswell Pk Canc Inst, Dept Pathol & Lab Med, Buffalo, NY 14263 USA
关键词
acute leukemia; CD99; chloroma; Ewing's/primitive neuroectodermal tumor; immunohistochemistry; MIC2;
D O I
10.1038/modpathol.3880077
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
MIC2 is characteristically expressed in lymphoblastic lesions and Ewing's/primitive neuroectodermal tumor sarcomas. Although MIC2 has recently been reported in chloroma and rare terminal deoxynucleotidyl transferase-positive acute myelogenous leukemia (AML), the incidence and the significance of MIC2 (CD99) immunoreactivity in myeloid lesions is not clear. In this study, we evaluated MIC2 positivity in a variety of myeloid diseases and normal marrow to determine its incidence and distribution in myeloid diseases; its correlation with dow cytometric and cytogenetic data in AML; and its association with leukemic transformation, relapse, and chloroma formation Paraffin sections of 11 chloromas and 94 bone marrow core biopsies from 66 patients were stained with CD99 monoclonal antibody 12E7. Of 94 bone marrow core biopsies, there were 30 AML, (fragment antigen binding M0 to M6), 23 remissions, 5 relapses, 12 myeloproliferative disorders, 13 myelodysplastic syndromes, and 11 normal marrows from patients who did not have leukemia CD99 immunoreactivity was evaluated with light microscopy. MIC2 expression was seen in leukemic blasts in 6 of 11 chloromas (55%) and 13 of 30 AML (43%) but rarely in myeloproliferative disorders, myelodysplastic syndromes, remission, and normal marrow CD99 tended to be positive in M1-, M3-, and HLA-Dr-negative AML and negative in AML with relapse. MICE expression did not correlate with the karyotype independent of French-American-British Cooperative Group classification and the disease remission or occurrence of chloroma in AML. We concluded that MIC2 is commonly expressed in leukemic blasts of AML and is not predictive of leukemic transformation from myeloproliferative disorders and myelodysplastic syndromes or chloroma formation. Caution should be taken when using MIC2 as a marker for Ewing's sarcoma/ primitive neuroectodermal tumor or lymphoblastic lymphoma on paraffin sections of either soft tissue or bone marrow specimens.
引用
收藏
页码:452 / 458
页数:7
相关论文
共 22 条
[1]  
COOPER K, 1995, APPL IMMUNOHISTOCHEM, V3, P198
[2]   INCIDENCE OF TDT POSITIVITY IN CASES OF LEUKEMIA AND LYMPHOMA [J].
DREXLER, HG ;
MENON, M ;
MINOWADA, J .
ACTA HAEMATOLOGICA, 1986, 75 (01) :12-17
[3]  
DREXLER HG, 1993, LEUKEMIA, V7, P1142
[4]   COMPARISON OF CELL-SURFACE ANTIGEN HBA71 (P30/32MIC2), NEURON-SPECIFIC ENOLASE, AND VIMENTIN IN THE IMMUNOHISTOCHEMICAL ANALYSIS OF EWINGS-SARCOMA OF BONE [J].
FELLINGER, EJ ;
GARINCHESA, P ;
GLASSER, DB ;
HUVOS, AG ;
RETTIG, WJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (08) :746-755
[5]  
FELLINGER EJ, 1991, CANCER RES, V51, P336
[6]  
GENLIN C, 1989, EMBO J, V8, P3253
[7]  
HAMILTON G, 1988, CANCER RES, V48, P6127
[8]   HUMAN THYMUS-LEUKEMIA ANTIGEN DEFINED BY HYBRIDOMA MONOCLONAL-ANTIBODIES [J].
LEVY, R ;
DILLEY, J ;
FOX, RI ;
WARNKE, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (12) :6552-6556
[9]  
LOCOCO F, 1989, HEMATOL ONCOL, V7, P167
[10]  
MEIS JM, 1986, CANCER-AM CANCER SOC, V58, P2697, DOI 10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO